Global Clinical Whole Exome Sequencing (WES) Supply, Demand and Key Producers, 2023-2029

Global Clinical Whole Exome Sequencing (WES) Supply, Demand and Key Producers, 2023-2029

The global Clinical Whole Exome Sequencing (WES) market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Clinical Whole Exome Sequencing (WES) is a comprehensive genetic test that identifies changes in a patient's DNA that cause or are related to their medical problems. By focusing on the entire protein-coding region of the genome (the exome), it provides the coverage needed to diagnose patients quickly and reliably.

This report studies the global Clinical Whole Exome Sequencing (WES) demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Clinical Whole Exome Sequencing (WES), and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Clinical Whole Exome Sequencing (WES) that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Clinical Whole Exome Sequencing (WES) total market, 2018-2029, (USD Million)

Global Clinical Whole Exome Sequencing (WES) total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Clinical Whole Exome Sequencing (WES) total market, key domestic companies and share, (USD Million)

Global Clinical Whole Exome Sequencing (WES) revenue by player and market share 2018-2023, (USD Million)

Global Clinical Whole Exome Sequencing (WES) total market by Type, CAGR, 2018-2029, (USD Million)

Global Clinical Whole Exome Sequencing (WES) total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Clinical Whole Exome Sequencing (WES) market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CentoXome, Mayo Clinic Laboratories, Baylor Genetics, Blueprint Genetics, GeneDx, CD Genomics, Illumina, Thermo Fisher and Labassure, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Clinical Whole Exome Sequencing (WES) market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Clinical Whole Exome Sequencing (WES) Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Clinical Whole Exome Sequencing (WES) Market, Segmentation by Type
Array-Based Exome Enrichment
Enrichment of the Exome in Solution using Biotinylated Probes

Global Clinical Whole Exome Sequencing (WES) Market, Segmentation by Application
Rare Genetic Disease
Genetic Testing Unsuccessful
Others

Companies Profiled:
CentoXome
Mayo Clinic Laboratories
Baylor Genetics
Blueprint Genetics
GeneDx
CD Genomics
Illumina
Thermo Fisher
Labassure
Yale Medicine
Genosalut
Caris Life Sciences
InterGenetics
Genomics and Pathology Services (GPS)
3billion
Broad Genomic
Roche
Novogene
BGI Genomics
Shanghai Jingzhou Genomics
Shihe Gene Biotechnology
JUNO Genomics

Key Questions Answered

1. How big is the global Clinical Whole Exome Sequencing (WES) market?

2. What is the demand of the global Clinical Whole Exome Sequencing (WES) market?

3. What is the year over year growth of the global Clinical Whole Exome Sequencing (WES) market?

4. What is the total value of the global Clinical Whole Exome Sequencing (WES) market?

5. Who are the major players in the global Clinical Whole Exome Sequencing (WES) market?